Antifibrotic Role of Nintedanib in Tracheal Stenosis After a Tracheal Wound

Abstract

Objectives/Hypothesis Tracheal stenosis is an obstructive disease of the upper airway that commonly develops as a result of abnormal wound healing. We evaluated the anti‐inflammatory and antifibrotic properties of nintedanib on tracheal stenosis both in vitro and in vivo. Study Design Prospective controlled animal study and in vitro comparative study of human cells. Methods An animal model of tracheal stenosis was induced via tracheal trauma. Postsurgical rats were orally administered with nintedanib (10 or 20 mg/kg/d) or saline (negative control) for 2 weeks, and tracheal specimens were harvested after 3 weeks. Degree of stenosis, collagen deposition, fibrotic surrogate markers expression, and T‐lymphocytic infiltration were evaluated. Human fetal lung fibroblast‐1 (HFL‐1) cells were cultured to determine the effects of nintedanib on changes of cellular biological function induced by transforming growth factor‐β1 (TGF‐β1). Results Rat tracheal stenotic tissues exhibited thickened lamina propria with irregular epithelium, characterized by significantly increased collagen deposition and elevated TGF‐β1, collagen I, α‐SMA and fibronectin expressions. Nintedanib markedly attenuated the tracheal stenotic lesions, reduced the collagen deposition and the expression of fibrotic marker proteins, and mitigated CD4+ T‐lymphocyte infiltration. Additionally, cellular proliferation and migration were decreased dose‐dependently in TGF‐β1‐stimulated HFL‐1 cells when treated with nintedanib. Furthermore, nintedanib inhibited TGF‐β1‐induced HFL‐1 differentiation and reduced the mRNA levels of the profibrotic genes. TGF‐β1‐activated phosphorylation of the TGF‐β/Smad2/3 and ERK1/2 pathways were also blocked by nintedanib. Conclusion Nintedanib effectively prevented tracheal stenosis in rats by inhibiting fibrosis and inflammation. The antifibrotic effect of nintedanib may be achieved by inhibiting fibroblasts' proliferation, migration and differentiation and suppressing the TGF‐β1/Smad2/3 and ERK1/2 signaling pathways. Level of Evidence NA Laryngoscope, 131:E2496–E2505, 2021

Radiotherapy-induced oxidative stress and fibrosis in breast cancer are suppressed by vactosertib, a novel, orally bioavailable TGF-β/ALK5 inhibitor

“…www.nature.com/scientificreports/ Differentiation of fibroblastic cells into myofibroblasts, which are the major source of ECM components and are considered significant effector cells of tissue fibrosis, is a primary process in the development of tissue fibrosis, and TGF-β induces this process 21 . α-Smooth muscle actin (α-SMA, a marker for a subset of myofibroblasts), FIBRONECTIN (an ECM component), and COL1A1 (a gene that produces a component of type I collagen) are used as markers for fibrosis 21,22 . Western blot analysis confirmed that the protein expression of α-SMA, COL1A1, and FIBRONECTIN was induced in irradiated primary tumors of 4T1-Luc allografted mice, and these increased markers were significantly decreased by co-treatment with vactosertib (Fig.…”

Molecular Mechanisms and Physiological Changes behind Benign Tracheal and Subglottic Stenosis in Adults

“…It targets the receptors of VEGF, PDGF and FGF and can interfere with both classic and non-classic TGF-Β1 signalling pathways. In a preclinical rat model, nintedanib proved to effectively prevent tracheal stenosis by inhibiting fibroblast proliferation, migration and differentiation, and by suppressing TGF-Β1/SMAD2/3 and ERK1/2 signalling pathways [ 89 ]. As suggested by preclinical data, there is a rationale for using drugs that specifically block TGF-Β pathway in LTS.…”

Inhalation Of Carboxymethyl Chitosan Alleviates Post-Traumatic Tracheal Fibrosis

“…Those benign diseases mainly include iatrogenic complications and trauma. Currently, many studies provide interesting perspectives in treatment strategies in iatrogenic complications after endotracheal intubation or tracheal tube insertion which lead to airway obstruction [8][9][10]. Wagner [11] have demonstrated that the outcome of keloids following burns are different from those developing after mechanical trauma.…”